Bank of New York Mellon Corp reduced its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 5.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,262,213 shares of the medical instruments supplier's stock after selling 140,897 shares during the quarter. Bank of New York Mellon Corp owned about 1.14% of DENTSPLY SIRONA worth $33,797,000 at the end of the most recent quarter.
A number of other institutional investors also recently modified their holdings of the business. Comerica Bank lifted its stake in DENTSPLY SIRONA by 41.2% in the 4th quarter. Comerica Bank now owns 225,080 shares of the medical instruments supplier's stock worth $4,272,000 after purchasing an additional 65,709 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in DENTSPLY SIRONA in the 4th quarter worth approximately $10,335,000. Cerity Partners LLC lifted its stake in DENTSPLY SIRONA by 268.5% in the 4th quarter. Cerity Partners LLC now owns 65,588 shares of the medical instruments supplier's stock worth $1,294,000 after purchasing an additional 47,788 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in DENTSPLY SIRONA by 39.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 53,903 shares of the medical instruments supplier's stock worth $805,000 after purchasing an additional 15,117 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in DENTSPLY SIRONA by 1,462.9% in the 1st quarter. GAMMA Investing LLC now owns 99,351 shares of the medical instruments supplier's stock worth $1,484,000 after purchasing an additional 92,994 shares in the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.
DENTSPLY SIRONA Stock Down 0.2%
NASDAQ:XRAY traded down $0.03 during mid-day trading on Thursday, hitting $15.79. 1,378,032 shares of the company's stock were exchanged, compared to its average volume of 2,909,513. The business has a fifty day moving average price of $16.08 and a 200 day moving average price of $16.34. The company has a market cap of $3.15 billion, a PE ratio of -3.47, a P/E/G ratio of 1.14 and a beta of 0.94. DENTSPLY SIRONA Inc. has a one year low of $12.16 and a one year high of $27.95. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.10 and a quick ratio of 0.76.
DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.14. The firm had revenue of $879.00 million for the quarter, compared to the consensus estimate of $854.75 million. DENTSPLY SIRONA had a negative net margin of 24.42% and a positive return on equity of 14.31%. The business's revenue was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.42 earnings per share. Equities analysts predict that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current year.
DENTSPLY SIRONA Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, July 11th. Investors of record on Friday, June 27th were given a dividend of $0.16 per share. The ex-dividend date of this dividend was Friday, June 27th. This represents a $0.64 dividend on an annualized basis and a yield of 4.05%. DENTSPLY SIRONA's dividend payout ratio (DPR) is -14.10%.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on XRAY. Piper Sandler lowered their target price on shares of DENTSPLY SIRONA from $20.00 to $16.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Barrington Research increased their target price on shares of DENTSPLY SIRONA from $20.00 to $21.00 and gave the company an "outperform" rating in a report on Monday, May 12th. UBS Group reduced their target price on shares of DENTSPLY SIRONA from $27.00 to $25.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Wall Street Zen raised shares of DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a report on Sunday. Finally, Morgan Stanley lowered shares of DENTSPLY SIRONA from an "overweight" rating to an "equal weight" rating and set a $14.00 target price on the stock. in a report on Tuesday, April 15th. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $20.36.
View Our Latest Stock Analysis on DENTSPLY SIRONA
DENTSPLY SIRONA Company Profile
(
Free Report)
DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.
Featured Stories

Before you consider DENTSPLY SIRONA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DENTSPLY SIRONA wasn't on the list.
While DENTSPLY SIRONA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.